Tapentadol is effective in the management of moderate-to-severe cancer-related pain in opioid-naïve and opioid-tolerant patients: a retrospective study

PURPOSE: Tapentadol is a dual-acting mu-opioid receptor agonist and noradrenaline reuptake inhibitor with non-inferior analgesic efficacy to oxycodone and better gastrointestinal tolerability than full mu-opioid receptor agonists. Tapentadol is approved for cancer pain in Japan; however, real-world...

Descripción completa

Detalles Bibliográficos
Autores principales: Sazuka, Shoichiro, Koitabashi, Toshiya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7674340/
https://www.ncbi.nlm.nih.gov/pubmed/32648017
http://dx.doi.org/10.1007/s00540-020-02821-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7674340/
https://www.ncbi.nlm.nih.gov/pubmed/32648017
http://dx.doi.org/10.1007/s00540-020-02821-8

Ejemplares similares